Variables | Number of patients (%) | P | |
---|---|---|---|
PCI (n = 26) | No PCI (n = 81) | ||
Age (year) | |||
Median (range) | 60 (43‒76) | 69 (44‒82) | 0.001 |
Gender | |||
Male | 22 (85) | 69 (85) | 1.000 |
Female | 4 (15) | 12 (15) | |
ECOG performance scorea | |||
0‒1 | 21 (81) | 55 (68) | 1.000 |
≥ 2 | 3 (12) | 8 (10) | |
Ever-smokera | |||
No | 1 (4) | 9 (11) | 0.445 |
Yes | 25 (96) | 70 (86) | |
Body mass index (kg/m2) | |||
Median (range) | 24.1 (15.8‒29.4) | 23.8 (15.4‒32.7) | 0.776 |
No. of symptoms at diagnosis | |||
Median (range) | 2 (0‒3) | 1 (0‒4) | 0.608 |
Clinical T stagea | |||
T1‒2 | 13 (56) | 31 (50) | 0.593 |
T3‒4 | 10 (44) | 31 (50) | |
Clinical N stagea | |||
N0‒1 | 2 (8) | 18 (22) | 0.147 |
N2‒3 | 23 (92) | 62 (78) | |
Definitive treatment | |||
Chemoradiotherapyb | 19 (73) | 38 (47) | 0.055 |
Chemotherapy | 6 (23) | 31 (38) | |
Othersc | 1 (4) | 12 (15) | |
Chemotherapy regimens | |||
Cisplatin-based doublet | 19 (73) | 48 (68) | 0.551 |
Carboplatin-based doublet | 6 (23) | 20 (28) | |
Others | 1 (4) | 3 (4) | |
Cycles of first-line chemotherapy | |||
< 4 | 1 (4) | 27 (38) | 0.001 |
≥ 4 | 25 (96) | 44 (62) | |
Salvage treatment | |||
Chemoradiotherapyb | 5 (19) | 10 (12) | 0.676 |
Chemotherapy | 5 (19) | 11 (14) | |
Othersc | 2 (8) | 8 (10) | |
No treatment | 14 (54) | 52 (64) |